{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:06:01Z","timestamp":1793210761594,"version":"4.5.0"},"reference-count":107,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,1,6]],"date-time":"2015-01-06T00:00:00Z","timestamp":1420502400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1038\/nrneurol.2014.253","type":"journal-article","created":{"date-parts":[[2015,1,6]],"date-time":"2015-01-06T09:49:38Z","timestamp":1420537778000},"page":"80-89","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":286,"title":["Intravenous immunoglobulin in neurology\u2014mode of action and clinical efficacy"],"prefix":"10.1038","volume":"11","author":[{"given":"Jan D.","family":"L\u00fcnemann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Falk","family":"Nimmerjahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marinos C.","family":"Dalakas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,1,6]]},"reference":[{"key":"BFnrneurol2014253_CR1","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/nrmicro974","volume":"2","author":"A Casadevall","year":"2004","unstructured":"Casadevall, A., Dadachova, E. & Pirofski, L. A. Passive antibody therapy for infectious diseases. Nat. Rev. Microbiol. 2, 695\u2013703 (2004).","journal-title":"Nat. Rev. Microbiol."},{"key":"BFnrneurol2014253_CR2","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1126\/science.282.5388.490","volume":"282","author":"I Viard","year":"1998","unstructured":"Viard, I. et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 282, 490\u2013493 (1998).","journal-title":"Science"},{"key":"BFnrneurol2014253_CR3","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1196\/annals.1423.044","volume":"1110","author":"L Le Pottier","year":"2007","unstructured":"Le Pottier, L. et al. Intravenous immunoglobulin and cytokines: focus on tumor necrosis factor family members BAFF and APRIL. Ann. N. Y. Acad. Sci. 1110, 426\u2013432 (2007).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"BFnrneurol2014253_CR4","doi-asserted-by":"crossref","first-page":"206","DOI":"10.2340\/00015555-0249","volume":"87","author":"C Prins","year":"2007","unstructured":"Prins, C., Gelfand, E. W. & French, L. E. Intravenous immunoglobulin: properties, mode of action and practical use in dermatology. Acta Derm. Venereol. 87, 206\u2013218 (2007).","journal-title":"Acta Derm. Venereol."},{"key":"BFnrneurol2014253_CR5","doi-asserted-by":"crossref","first-page":"4104","DOI":"10.4049\/jimmunol.143.12.4104","volume":"143","author":"F Rossi","year":"1989","unstructured":"Rossi, F. & Kazatchkine, M. D. Antiidiotypes against autoantibodies in pooled normal human polyspecific Ig. J. Immunol. 143, 4104\u20134109 (1989).","journal-title":"J. Immunol."},{"key":"BFnrneurol2014253_CR6","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/nri3401","volume":"13","author":"I Schwab","year":"2013","unstructured":"Schwab, I. & Nimmerjahn, F. Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat. Rev. Immunol. 13, 176\u2013189 (2013).","journal-title":"Nat. Rev. Immunol."},{"key":"BFnrneurol2014253_CR7","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1365-2249.1993.tb03407.x","volume":"92","author":"T Vassilev","year":"1993","unstructured":"Vassilev, T. et al. Antibodies to the CD5 molecule in normal human immunoglobulins for therapeutic use (intravenous immunoglobulins, IVIg). Clin. Exp. Immunol. 92, 369\u2013372 (1993).","journal-title":"Clin. Exp. Immunol."},{"key":"BFnrneurol2014253_CR8","doi-asserted-by":"crossref","first-page":"3624","DOI":"10.1182\/blood.V93.11.3624","volume":"93","author":"TL Vassilev","year":"1999","unstructured":"Vassilev, T. L. et al. Inhibition of cell adhesion by antibodies to Arg\u2013Gly\u2013Asp (RGD) in normal immunoglobulin for therapeutic use (intravenous immunoglobulin, IVIg). Blood 93, 3624\u20133631 (1999).","journal-title":"Blood"},{"key":"BFnrneurol2014253_CR9","doi-asserted-by":"crossref","first-page":"4255","DOI":"10.1182\/blood-2006-05-021568","volume":"108","author":"S von Gunten","year":"2006","unstructured":"von Gunten, S. et al. Immunologic and functional evidence for anti-Siglec-9 autoantibodies in intravenous immunoglobulin preparations. Blood 108, 4255\u20134259 (2006).","journal-title":"Blood"},{"key":"BFnrneurol2014253_CR10","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.autrev.2008.03.015","volume":"7","author":"S von Gunten","year":"2008","unstructured":"von Gunten, S. & Simon, H. U. Natural anti-Siglec autoantibodies mediate potential immunoregulatory mechanisms: implications for the clinical use of intravenous immunoglobulins (IVIg). Autoimmun. Rev. 7, 453\u2013456 (2008).","journal-title":"Autoimmun. Rev."},{"key":"BFnrneurol2014253_CR11","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.jaci.2009.03.013","volume":"123","author":"S von Gunten","year":"2009","unstructured":"von Gunten, S. et al. Intravenous immunoglobulin contains a broad repertoire of anti-carbohydrate antibodies that is not restricted to the IgG2 subclass. J. Allergy Clin. Immunol. 123, 1268\u20131276.e15 (2009).","journal-title":"J. Allergy Clin. Immunol."},{"key":"BFnrneurol2014253_CR12","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.jaci.2007.01.023","volume":"119","author":"S von Gunten","year":"2007","unstructured":"von Gunten, S. et al. Intravenous immunoglobulin preparations contain anti-Siglec-8 autoantibodies. J. Allergy Clin. Immunol. 119, 1005\u20131011 (2007).","journal-title":"J. Allergy Clin. Immunol."},{"key":"BFnrneurol2014253_CR13","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1182\/blood.V74.1.326.326","volume":"74","author":"M Basta","year":"1989","unstructured":"Basta, M., Langlois, P. F., Marques, M., Frank, M. M. & Fries, L. F. High-dose intravenous immunoglobulin modifies complement-mediated in vivo clearance. Blood 74, 326\u2013333 (1989).","journal-title":"Blood"},{"key":"BFnrneurol2014253_CR14","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/0140-6736(93)92000-J","volume":"342","author":"M Debre","year":"1993","unstructured":"Debre, M. et al. Infusion of Fc\u03b3 fragments for treatment of children with acute immune thrombocytopenic purpura. Lancet 342, 945\u2013949 (1993).","journal-title":"Lancet"},{"key":"BFnrneurol2014253_CR15","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1126\/science.1154315","volume":"320","author":"RM Anthony","year":"2008","unstructured":"Anthony, R. M. et al. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 320, 373\u2013376 (2008).","journal-title":"Science"},{"key":"BFnrneurol2014253_CR16","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S1074-7613(03)00080-3","volume":"18","author":"P Bruhns","year":"2003","unstructured":"Bruhns, P., Samuelsson, A., Pollard, J. W. & Ravetch, J. V. Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease. Immunity 18, 573\u2013581 (2003).","journal-title":"Immunity"},{"key":"BFnrneurol2014253_CR17","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1084\/jem.20051900","volume":"203","author":"Y Kaneko","year":"2006","unstructured":"Kaneko, Y., Nimmerjahn, F., Madaio, M. P. & Ravetch, J. V. Pathology and protection in nephrotoxic nephritis is determined by selective engagement of specific Fc receptors. J. Exp. Med. 203, 789\u2013797 (2006).","journal-title":"J. Exp. Med."},{"key":"BFnrneurol2014253_CR18","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1126\/science.1129594","volume":"313","author":"Y Kaneko","year":"2006","unstructured":"Kaneko, Y., Nimmerjahn, F. & Ravetch, J. V. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313, 670\u2013673 (2006).","journal-title":"Science"},{"key":"BFnrneurol2014253_CR19","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1126\/science.291.5503.484","volume":"291","author":"A Samuelsson","year":"2001","unstructured":"Samuelsson, A., Towers, T. L. & Ravetch, J. V. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 291, 484\u2013486 (2001).","journal-title":"Science"},{"key":"BFnrneurol2014253_CR20","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1055\/s-0037-1613331","volume":"88","author":"RJ Hansen","year":"2002","unstructured":"Hansen, R. J. & Balthasar, J. P. Intravenous immunoglobulin mediates an increase in anti-platelet antibody clearance via the FcRn receptor. Thromb. Haemost. 88, 898\u2013899 (2002).","journal-title":"Thromb. Haemost."},{"key":"BFnrneurol2014253_CR21","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1172\/JCI24394","volume":"115","author":"N Li","year":"2005","unstructured":"Li, N. et al. Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases. J. Clin. Invest. 115, 3440\u20133450 (2005).","journal-title":"J. Clin. Invest."},{"key":"BFnrneurol2014253_CR22","doi-asserted-by":"crossref","first-page":"4788","DOI":"10.1073\/pnas.0807319106","volume":"106","author":"B Tackenberg","year":"2009","unstructured":"Tackenberg, B. et al. Impaired inhibitory Fc\u03b3 receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy. Proc. Natl Acad. Sci. USA 106, 4788\u20134792 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrneurol2014253_CR23","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1084\/jem.20051503","volume":"203","author":"M Mackay","year":"2006","unstructured":"Mackay, M. et al. Selective dysregulation of the Fc\u03b3IIB receptor on memory B cells in SLE. J. Exp. Med. 203, 2157\u20132164 (2006).","journal-title":"J. Exp. Med."},{"key":"BFnrneurol2014253_CR24","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature10134","volume":"475","author":"RM Anthony","year":"2011","unstructured":"Anthony, R. M., Kobayashi, T., Wermeling, F. & Ravetch, J. V. Intravenous gammaglobulin suppresses inflammation through a novel TH2 pathway. Nature 475, 110\u2013113 (2011).","journal-title":"Nature"},{"key":"BFnrneurol2014253_CR25","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1084\/jem.20051900","volume":"203","author":"Y Kaneko","year":"2006","unstructured":"Kaneko, Y., Nimmerjahn, F., Madaio, M. P. & Ravetch, J. V. Pathology and protection in nephrotoxic nephritis is determined by selective engagement of specific Fc receptors. J. Exp. Med. 203, 789\u2013797 (2006).","journal-title":"J. Exp. Med."},{"key":"BFnrneurol2014253_CR26","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1146\/annurev.immunol.25.022106.141702","volume":"25","author":"JN Arnold","year":"2007","unstructured":"Arnold, J. N., Wormald, M. R., Sim, R. B., Rudd, P. M. & Dwek, R. A. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu. Rev. Immunol. 25, 21\u201350 (2007).","journal-title":"Annu. Rev. Immunol."},{"key":"BFnrneurol2014253_CR27","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/eji.201142260","volume":"42","author":"I Schwab","year":"2012","unstructured":"Schwab, I., Biburger, M., Kronke, G., Schett, G. & Nimmerjahn, F. IVIg-mediated amelioration of ITP in mice is dependent on sialic acid and SIGNR1. Eur. J. Immunol. 42, 826\u2013830 (2012).","journal-title":"Eur. J. Immunol."},{"key":"BFnrneurol2014253_CR28","doi-asserted-by":"crossref","first-page":"5031","DOI":"10.4049\/jimmunol.1301611","volume":"192","author":"IK Campbell","year":"2014","unstructured":"Campbell, I. K. et al. Therapeutic effect of IVIG on inflammatory arthritis in mice is dependent on the Fc portion and independent of sialylation or basophils. J. Immunol. 192, 5031\u20135038 (2014).","journal-title":"J. Immunol."},{"key":"BFnrneurol2014253_CR29","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1002\/eji.201444440","volume":"44","author":"S Othy","year":"2014","unstructured":"Othy, S. et al. Sialylation may be dispensable for reciprocal modulation of helper T cells by intravenous immunoglobulin. Eur. J. Immunol. 44, 2059\u20132063 (2014).","journal-title":"Eur. J. Immunol."},{"key":"BFnrneurol2014253_CR30","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1002\/(SICI)1097-4598(199911)22:11<1479::AID-MUS3>3.0.CO;2-B","volume":"22","author":"MC Dalakas","year":"1999","unstructured":"Dalakas, M. C. Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines. Muscle Nerve 22, 1479\u20131497 (1999).","journal-title":"Muscle Nerve"},{"key":"BFnrneurol2014253_CR31","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nrneurol.2011.121","volume":"7","author":"MC Dalakas","year":"2011","unstructured":"Dalakas, M. C. Advances in the diagnosis, pathogenesis and treatment of CIDP. Nat. Rev. Neurol. 7, 507\u2013517 (2011).","journal-title":"Nat. Rev. Neurol."},{"key":"BFnrneurol2014253_CR32","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1056\/NEJM199204233261705","volume":"326","author":"FG van der Meche","year":"1992","unstructured":"van der Meche, F. G. & Schmitz, P. I. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain\u2013Barr\u00e9 syndrome. Dutch Guillain\u2013Barr\u00e9 Study Group. N. Engl. J. Med. 326, 1123\u20131129 (1992).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneurol2014253_CR33","doi-asserted-by":"crossref","unstructured":"[No authors listed]. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain\u2013Barr\u00e9 syndrome. Plasma Exchange\/Sandoglobulin Guillain\u2013Barr\u00e9 Syndrome Trial Group. Lancet 349, 225\u2013230 (1997).","DOI":"10.1016\/S0140-6736(96)09095-2"},{"issue":"Suppl. 1","key":"BFnrneurol2014253_CR34","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1365-2249.2009.04025.x","volume":"158","author":"RA Hughes","year":"2009","unstructured":"Hughes, R. A. et al. Clinical applications of intravenous immunoglobulins in neurology. Clin. Exp. Immunol. 158 (Suppl. 1), 34\u201342 (2009).","journal-title":"Clin. Exp. Immunol."},{"key":"BFnrneurol2014253_CR35","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/ana.21737","volume":"66","author":"K Kuitwaard","year":"2009","unstructured":"Kuitwaard, K. et al. Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain\u2013Barr\u00e9 syndrome. Ann. Neurol. 66, 597\u2013603 (2009).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol2014253_CR36","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/ana.410360607","volume":"36","author":"PJ Dyck","year":"1994","unstructured":"Dyck, P. J. et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann. Neurol. 36, 838\u2013845 (1994).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol2014253_CR37","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/ana.1088","volume":"50","author":"R Hughes","year":"2001","unstructured":"Hughes, R. et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann. Neurol. 50, 195\u2013201 (2001).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol2014253_CR38","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1212\/WNL.56.4.445","volume":"56","author":"JR Mendell","year":"2001","unstructured":"Mendell, J. R. et al. Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 56, 445\u2013449 (2001).","journal-title":"Neurology"},{"key":"BFnrneurol2014253_CR39","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S1474-4422(07)70329-0","volume":"7","author":"RA Hughes","year":"2008","unstructured":"Hughes, R. A. et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol. 7, 136\u2013144 (2008).","journal-title":"Lancet Neurol."},{"key":"BFnrneurol2014253_CR40","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1212\/WNL.0b013e3181a0fd80","volume":"72","author":"IS Merkies","year":"2009","unstructured":"Merkies, I. S. et al. Health-related quality-of-life improvements in CIDP with immune globulin IV 10%: the ICE Study. Neurology 72, 1337\u20131344 (2009).","journal-title":"Neurology"},{"key":"BFnrneurol2014253_CR41","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/mus.21236","volume":"39","author":"V Bril","year":"2009","unstructured":"Bril, V. et al. Electrophysiology in chronic inflammatory demyelinating polyneuropathy with IGIV. Muscle Nerve 39, 448\u2013455 (2009).","journal-title":"Muscle Nerve"},{"key":"BFnrneurol2014253_CR42","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1001\/archneurol.2010.105","volume":"67","author":"N Latov","year":"2010","unstructured":"Latov, N. et al. Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. Arch. Neurol. 67, 802\u2013807 (2010).","journal-title":"Arch. Neurol."},{"key":"BFnrneurol2014253_CR43","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/jnnp.56.1.36","volume":"56","author":"M Vermeulen","year":"1993","unstructured":"Vermeulen, M. et al. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study. J. Neurol. Neurosurg. Psychiatry 56, 36\u201339 (1993).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"BFnrneurol2014253_CR44","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/brain\/119.4.1067","volume":"119","author":"AF Hahn","year":"1996","unstructured":"Hahn, A. F., Bolton, C. F., Zochodne, D. & Feasby, T. E. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, cross-over study. Brain 119, 1067\u20131077 (1996).","journal-title":"Brain"},{"key":"BFnrneurol2014253_CR45","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1212\/WNL.0b013e3181bd1139","volume":"73","author":"M Iijima","year":"2009","unstructured":"Iijima, M. et al. Single nucleotide polymorphism of TAG-1 influences IVIg responsiveness of Japanese patients with CIDP. Neurology 73, 1348\u20131352 (2009).","journal-title":"Neurology"},{"key":"BFnrneurol2014253_CR46","doi-asserted-by":"publisher","unstructured":"Klehmet, J. et al. Effective treatment with intravenous immunoglobulins reduces autoreactive T-cell response in patients with CIDP. J. Neurol. Neurosurg. Psychiatry http:\/\/dx.doi.org\/10.1136\/jnnp-2014-307708 .","DOI":"10.1136\/jnnp-2014-307708"},{"key":"BFnrneurol2014253_CR47","doi-asserted-by":"publisher","unstructured":"Dalakas, M. C. Pathogenesis of immune-mediated neuropathies. Biochim. Biophys. Acta http:\/\/dx.doi.org\/10.1016\/j.bbadis.2014.06.013 .","DOI":"10.1016\/j.bbadis.2014.06.013"},{"key":"BFnrneurol2014253_CR48","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/jns5.12046","volume":"18","author":"AF Hahn","year":"2013","unstructured":"Hahn, A. F. et al. A controlled trial of intravenous immunoglobulin in multifocal motor neuropathy. J. Peripher. Nerv. Syst. 18, 321\u2013330 (2013).","journal-title":"J. Peripher. Nerv. Syst."},{"key":"BFnrneurol2014253_CR49","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1212\/WNL.55.9.1256","volume":"55","author":"P Federico","year":"2000","unstructured":"Federico, P., Zochodne, D. W., Hahn, A. F., Brown, W. F. & Feasby, T. E. Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study. Neurology 55, 1256\u20131262 (2000).","journal-title":"Neurology"},{"key":"BFnrneurol2014253_CR50","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/ana.410400516","volume":"40","author":"MC Dalakas","year":"1996","unstructured":"Dalakas, M. C. et al. A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy. Ann. Neurol. 40, 792\u2013795 (1996).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol2014253_CR51","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1007\/s00415-002-0808-z","volume":"249","author":"G Comi","year":"2002","unstructured":"Comi, G. et al. A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy. J. Neurol. 249, 1370\u20131377 (2002).","journal-title":"J. Neurol."},{"key":"BFnrneurol2014253_CR52","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1038\/nbt1143","volume":"23","author":"C Vaccaro","year":"2005","unstructured":"Vaccaro, C., Zhou, J., Ober, R. J. & Ward, E. S. Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels. Nat. Biotechnol. 23, 1283\u20131288 (2005).","journal-title":"Nat. Biotechnol."},{"key":"BFnrneurol2014253_CR53","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/01.TP.0000437671.78716.f3","volume":"97","author":"D Barbosa","year":"2013","unstructured":"Barbosa, D. et al. Polyomavirus BK viremia in kidney transplant recipients after desensitization with IVIg and rituximab. Transplantation 97, 755\u2013761 (2013).","journal-title":"Transplantation"},{"key":"BFnrneurol2014253_CR54","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1097\/TP.0b013e3182845fe1","volume":"95","author":"SC Jordan","year":"2013","unstructured":"Jordan, S. C., Vo, A., Lai, C. H. & Reinsmoen, N. Defining the benefits of desensitization therapy. Transplantation 95, e31\u2013e32 (2013).","journal-title":"Transplantation"},{"key":"BFnrneurol2014253_CR55","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1378\/chest.12-2907","volume":"144","author":"IF Hung","year":"2013","unstructured":"Hung, I. F. et al. Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A (H1N1) infection. Chest 144, 464\u2013473 (2013).","journal-title":"Chest"},{"key":"BFnrneurol2014253_CR56","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/ana.410410615","volume":"41","author":"P Gajdos","year":"1997","unstructured":"Gajdos, P., Chevret, S., Clair, B., Tranchant, C. & Chastang, C. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group. Ann. Neurol. 41, 789\u2013796 (1997).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol2014253_CR57","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1001\/archneur.62.11.1689","volume":"62","author":"P Gajdos","year":"2005","unstructured":"Gajdos, P. et al. Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin: a randomized double-blind clinical trial. Arch. Neurol. 62, 1689\u20131693 (2005).","journal-title":"Arch. Neurol."},{"key":"BFnrneurol2014253_CR58","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1212\/01.wnl.0000256698.69121.45","volume":"68","author":"L Zinman","year":"2007","unstructured":"Zinman, L., Ng, E. & Bril, V. IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. Neurology 68, 837\u2013841 (2007).","journal-title":"Neurology"},{"key":"BFnrneurol2014253_CR59","doi-asserted-by":"publisher","unstructured":"Gajdos, P., Chevret, S. & Toyka, K. V. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database of Systematic Reviews, Issue 12. Art. No.: CD002277. http:\/\/dx.doi.org\/10.1002\/14651858.CD002277.pub4 .","DOI":"10.1002\/14651858.CD002277.pub4"},{"key":"BFnrneurol2014253_CR60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jns.2013.12.034","volume":"338","author":"MC Dalakas","year":"2014","unstructured":"Dalakas, M. C. IVIg in the chronic management of myasthenia gravis: is it enough for your money? J. Neurol. Sci. 338, 1\u20132 (2014).","journal-title":"J. Neurol. Sci."},{"key":"BFnrneurol2014253_CR61","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1001\/jama.291.19.2367","volume":"291","author":"MC Dalakas","year":"2004","unstructured":"Dalakas, M. C. Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA 291, 2367\u20132375 (2004).","journal-title":"JAMA"},{"key":"BFnrneurol2014253_CR62","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1212\/WNL.47.3.678","volume":"47","author":"PG Bain","year":"1996","unstructured":"Bain, P. G. et al. Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert\u2013Eaton myasthenic syndrome. Neurology 47, 678\u2013683 (1996).","journal-title":"Neurology"},{"key":"BFnrneurol2014253_CR63","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","volume":"329","author":"MC Dalakas","year":"1993","unstructured":"Dalakas, M. C. et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N. Engl. J. Med. 329, 1993\u20132000 (1993).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneurol2014253_CR64","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1172\/JCI117520","volume":"94","author":"M Basta","year":"1994","unstructured":"Basta, M. & Dalakas, M. C. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J. Clin. Invest. 94, 1729\u20131735 (1994).","journal-title":"J. Clin. Invest."},{"key":"BFnrneurol2014253_CR65","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1093\/brain\/awh518","volume":"128","author":"R Raju","year":"2005","unstructured":"Raju, R. & Dalakas, M. C. Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biological validation of clinically relevant genes. Brain 128, 1887\u20131896 (2005).","journal-title":"Brain"},{"key":"BFnrneurol2014253_CR66","doi-asserted-by":"crossref","first-page":"e1156","DOI":"10.7205\/MILMED-D-12-00509","volume":"178","author":"JA Chalela","year":"2013","unstructured":"Chalela, J. A. Guillain\u2013Barre variant in the deployed setting. Mil. Med. 178, e1156\u2013e1158 (2013).","journal-title":"Mil. Med."},{"key":"BFnrneurol2014253_CR67","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1182\/blood-2014-05-576835","volume":"124","author":"SQ Nagelkerke","year":"2014","unstructured":"Nagelkerke, S. Q. et al. Inhibition of Fc\u03b3R-mediated phagocytosis by IVIg is independent of IgG-Fc sialylation and Fc\u03b3RIIb in human macrophages. Blood 124, 3709\u20133718 (2014).","journal-title":"Blood"},{"key":"BFnrneurol2014253_CR68","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1212\/WNL.48.3.712","volume":"48","author":"MC Dalakas","year":"1997","unstructured":"Dalakas, M. C. et al. Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study. Neurology 48, 712\u2013716 (1997).","journal-title":"Neurology"},{"key":"BFnrneurol2014253_CR69","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1212\/WNL.51.6_Suppl_5.S37","volume":"51","author":"MC Dalakas","year":"1998","unstructured":"Dalakas, M. C. Controlled studies with high-dose intravenous immunoglobulin in the treatment of dermatomyositis, inclusion body myositis, and polymyositis. Neurology 51, S37\u2013S45 (1998).","journal-title":"Neurology"},{"key":"BFnrneurol2014253_CR70","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s004150050005","volume":"247","author":"MC Walter","year":"2000","unstructured":"Walter, M. C. et al. High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study. J. Neurol. 247, 22\u201328 (2000).","journal-title":"J. Neurol."},{"key":"BFnrneurol2014253_CR71","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1212\/WNL.56.3.323","volume":"56","author":"MC Dalakas","year":"2001","unstructured":"Dalakas, M. C. et al. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology 56, 323\u2013327 (2001).","journal-title":"Neurology"},{"key":"BFnrneurol2014253_CR72","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa01167","volume":"345","author":"MC Dalakas","year":"2001","unstructured":"Dalakas, M. C. et al. High-dose intravenous immune globulin for stiff-person syndrome. N. Engl. J. Med. 345, 1870\u20131876 (2001).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneurol2014253_CR73","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1212\/01.WNL.0000145798.61383.39","volume":"63","author":"PS Sorensen","year":"2004","unstructured":"Sorensen, P. S., Haas, J., Sellebjerg, F., Olsson, T. & Ravnborg, M. IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS. Neurology 63, 2028\u20132033 (2004).","journal-title":"Neurology"},{"key":"BFnrneurol2014253_CR74","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1191\/1352458504ms978sr","volume":"10","author":"LH Visser","year":"2004","unstructured":"Visser, L. H. et al. A randomized, double-blind, placebo-controlled pilot study of i.v. immune globulins in combination with i.v. methylprednisolone in the treatment of relapses in patients with MS. Mult. Scler. 10, 89\u201391 (2004).","journal-title":"Mult. Scler."},{"key":"BFnrneurol2014253_CR75","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1212\/01.wnl.0000318281.98220.6f","volume":"71","author":"F Fazekas","year":"2008","unstructured":"Fazekas, F. et al. Intravenous immunoglobulin in relapsing\u2013remitting multiple sclerosis: a dose-finding trial. Neurology 71, 265\u2013271 (2008).","journal-title":"Neurology"},{"key":"BFnrneurol2014253_CR76","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(04)17101-8","volume":"364","author":"OR Hommes","year":"2004","unstructured":"Hommes, O. R. et al. Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial. Lancet 364, 1149\u20131156 (2004).","journal-title":"Lancet"},{"key":"BFnrneurol2014253_CR77","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1007\/s00415-004-0495-z","volume":"251","author":"A Achiron","year":"2004","unstructured":"Achiron, A. et al. Effect of intravenous immunoglobulin treatment on pregnancy and postpartum-related relapses in multiple sclerosis. J. Neurol. 251, 1133\u20131137 (2004).","journal-title":"J. Neurol."},{"key":"BFnrneurol2014253_CR78","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1136\/jnnp.2003.033399","volume":"75","author":"RC Dodel","year":"2004","unstructured":"Dodel, R. C. et al. Intravenous immunoglobulins containing antibodies against \u03b2-amyloid for the treatment of Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 75, 1472\u20131474 (2004).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"BFnrneurol2014253_CR79","doi-asserted-by":"crossref","first-page":"8850","DOI":"10.1073\/pnas.151261398","volume":"98","author":"RB DeMattos","year":"2001","unstructured":"DeMattos, R. B. et al. Peripheral anti-A\u03b2 antibody alters CNS and plasma A\u03b2 clearance and decreases brain A\u03b2 burden in a mouse model of Alzheimer's disease. Proc. Natl Acad. Sci. USA 98, 8850\u20138855 (2001).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrneurol2014253_CR80","doi-asserted-by":"crossref","first-page":"641","DOI":"10.2217\/bmm.14.2","volume":"8","author":"P Leoyklang","year":"2014","unstructured":"Leoyklang, P. et al. Sialylation of Thomsen\u2013Friedenreich antigen is a noninvasive blood-based biomarker for GNE myopathy. Biomark. Med. 8, 641\u2013652 (2014).","journal-title":"Biomark. Med."},{"key":"BFnrneurol2014253_CR81","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1016\/j.jmb.2014.07.006","volume":"426","author":"AA Ahmed","year":"2014","unstructured":"Ahmed, A. A. et al. Structural characterization of anti-inflammatory immunoglobulin G Fc proteins. J. Mol. Biol. 426, 3166\u20133179 (2014).","journal-title":"J. Mol. Biol."},{"key":"BFnrneurol2014253_CR82","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S1474-4422(06)70447-1","volume":"5","author":"H Gonzalez","year":"2006","unstructured":"Gonzalez, H. et al. Intravenous immunoglobulin for post-polio syndrome: a randomised controlled trial. Lancet Neurol. 5, 493\u2013500 (2006).","journal-title":"Lancet Neurol."},{"key":"BFnrneurol2014253_CR83","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/j.1399-0039.1984.tb02144.x","volume":"24","author":"T Juji","year":"1984","unstructured":"Juji, T., Satake, M., Honda, Y. & Doi, Y. HLA antigens in Japanese patients with narcolepsy. All the patients were DR2 positive. Tissue Antigens 24, 316\u2013319 (1984).","journal-title":"Tissue Antigens"},{"key":"BFnrneurol2014253_CR84","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1056\/NEJM200103013440918","volume":"344","author":"E Mignot","year":"2001","unstructured":"Mignot, E. & Thorsby, E. Narcolepsy and the HLA system. N. Engl. J. Med. 344, 692 (2001).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneurol2014253_CR85","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1007\/s00415-008-0983-7","volume":"255","author":"G Plazzi","year":"2008","unstructured":"Plazzi, G. et al. Intravenous high-dose immunoglobulin treatment in recent onset childhood narcolepsy with cataplexy. J. Neurol. 255, 1549\u20131554 (2008).","journal-title":"J. Neurol."},{"key":"BFnrneurol2014253_CR86","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nri3401-c1","volume":"14","author":"S von Gunten","year":"2014","unstructured":"von Gunten, S. et al. IVIG pluripotency and the concept of Fc-sialylation: challenges to the scientist. Nat. Rev. Immunol. 14, 349 (2014).","journal-title":"Nat. Rev. Immunol."},{"key":"BFnrneurol2014253_CR87","doi-asserted-by":"crossref","first-page":"152","DOI":"10.7326\/0003-4819-152-3-201002020-00006","volume":"152","author":"A Goebel","year":"2010","unstructured":"Goebel, A. et al. Intravenous immunoglobulin treatment of the complex regional pain syndrome: a randomized trial. Ann. Intern. Med. 152, 152\u2013158 (2010).","journal-title":"Ann. Intern. Med."},{"key":"BFnrneurol2014253_CR88","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1177\/1352458513495938","volume":"20","author":"L Elsone","year":"2014","unstructured":"Elsone, L. et al. Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients. Mult. Scler. 20, 501\u2013504 (2014).","journal-title":"Mult. Scler."},{"key":"BFnrneurol2014253_CR89","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1021\/pr401213z","volume":"13","author":"WJ Fokkink","year":"2014","unstructured":"Fokkink, W. J. et al. IgG Fc N-glycosylation in Guillain\u2013Barr\u00e9 syndrome treated with immunoglobulins. J. Proteome Res. 13, 1722\u20131730 (2014).","journal-title":"J. Proteome Res."},{"key":"BFnrneurol2014253_CR90","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/mus.21433","volume":"40","author":"PD Donofrio","year":"2009","unstructured":"Donofrio, P. D. et al. Consensus statement: the use of intravenous immunoglobulin in the treatment of neuromuscular conditions report of the AANEM ad hoc committee. Muscle Nerve 40, 890\u2013900 (2009).","journal-title":"Muscle Nerve"},{"key":"BFnrneurol2014253_CR91","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0140-6736(86)92511-0","volume":"2","author":"RK Woodruff","year":"1986","unstructured":"Woodruff, R. K., Grigg, A. P., Firkin, F. C. & Smith, I. L. Fatal thrombotic events during treatment of autoimmune thrombocytopenia with intravenous immunoglobulin in elderly patients. Lancet 2, 217\u2013218 (1986).","journal-title":"Lancet"},{"key":"BFnrneurol2014253_CR92","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1212\/01.WNL.0000074394.15882.83","volume":"60","author":"MC Dalakas","year":"2003","unstructured":"Dalakas, M. C. & Clark, W. M. Strokes, thromboembolic events, and IVIg: rare incidents blemish an excellent safety record. Neurology 60, 1736\u20131737 (2003).","journal-title":"Neurology"},{"key":"BFnrneurol2014253_CR93","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1212\/WNL.44.2.223","volume":"44","author":"MC Dalakas","year":"1994","unstructured":"Dalakas, M. C. High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events. Neurology 44, 223\u2013226 (1994).","journal-title":"Neurology"},{"key":"BFnrneurol2014253_CR94","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1212\/WNL.46.1.250","volume":"46","author":"R Voltz","year":"1996","unstructured":"Voltz, R., Rosen, F. V., Yousry, T., Beck, J. & Hohlfeld, R. Reversible encephalopathy with cerebral vasospasm in a Guillain\u2013Barr\u00e9 syndrome patient treated with intravenous immunoglobulin. Neurology 46, 250\u2013251 (1996).","journal-title":"Neurology"},{"key":"BFnrneurol2014253_CR95","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.biologicals.2014.04.002","volume":"42","author":"WA Germishuizen","year":"2014","unstructured":"Germishuizen, W. A., Gyure, D. C., Stubbings, D. & Burnouf, T. Quantifying the thrombogenic potential of human plasma-derived immunoglobulin products. Biologicals 42, 260\u2013270 (2014).","journal-title":"Biologicals"},{"key":"BFnrneurol2014253_CR96","doi-asserted-by":"crossref","first-page":"721","DOI":"10.7326\/0003-4819-126-9-199705010-00008","volume":"126","author":"MC Dalakas","year":"1997","unstructured":"Dalakas, M. C. Intravenous immune globulin therapy for neurologic diseases. Ann. Intern. Med. 126, 721\u2013730 (1997).","journal-title":"Ann. Intern. Med."},{"issue":"Suppl. 6","key":"BFnrneurol2014253_CR97","doi-asserted-by":"crossref","first-page":"70S","DOI":"10.1007\/BF01540896","volume":"15","author":"MC Dalakas","year":"1995","unstructured":"Dalakas, M. C. Update on the use of intravenous immune globulin in the treatment of patients with inflammatory muscle disease. J. Clin. Immunol. 15 (Suppl. 6), 70S\u201375S (1995).","journal-title":"J. Clin. Immunol."},{"key":"BFnrneurol2014253_CR98","doi-asserted-by":"crossref","first-page":"259","DOI":"10.7326\/0003-4819-121-4-199408150-00004","volume":"121","author":"EA Sekul","year":"1994","unstructured":"Sekul, E. A., Cupler, E. J. & Dalakas, M. C. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann. Intern. Med. 121, 259\u2013262 (1994).","journal-title":"Ann. Intern. Med."},{"key":"BFnrneurol2014253_CR99","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/BF00915419","volume":"7","author":"J Bjorkander","year":"1987","unstructured":"Bjorkander, J. et al. Immunoglobulin prophylaxis in patients with antibody deficiency syndromes and anti-IgA antibodies. J. Clin. Immunol. 7, 8\u201315 (1987).","journal-title":"J. Clin. Immunol."},{"key":"BFnrneurol2014253_CR100","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.clim.2006.10.002","volume":"122","author":"J Horn","year":"2007","unstructured":"Horn, J. et al. Anti-IgA antibodies in common variable immunodeficiency (CVID): diagnostic workup and therapeutic strategy. Clin. Immunol. 122, 156\u2013162 (2007).","journal-title":"Clin. Immunol."},{"key":"BFnrneurol2014253_CR101","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1056\/NEJM198602273140907","volume":"314","author":"AW Burks","year":"1986","unstructured":"Burks, A. W., Sampson, H. A. & Buckley, R. H. Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulinemia. N. Engl. J. Med. 314, 560\u2013564 (1986).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneurol2014253_CR102","first-page":"157","volume":"11","author":"N Ahsan","year":"1998","unstructured":"Ahsan, N. Intravenous immunoglobulin induced-nephropathy: a complication of IVIG therapy. J. Nephrol. 11, 157\u2013161 (1998).","journal-title":"J. Nephrol."},{"key":"BFnrneurol2014253_CR103","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1001\/archinte.154.17.1985","volume":"154","author":"N Ahsan","year":"1994","unstructured":"Ahsan, N., Palmer, B. F., Wheeler, D., Greenlee, R. G. Jr & Toto, R. D. Intravenous immunoglobulin-induced osmotic nephrosis. Arch. Intern. Med. 154, 1985\u20131987 (1994).","journal-title":"Arch. Intern. Med."},{"key":"BFnrneurol2014253_CR104","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1056\/NEJMc1214823","volume":"368","author":"EW Gelfand","year":"2013","unstructured":"Gelfand, E. W. Intravenous immune globulin in autoimmune and inflammatory diseases. N. Engl. J. Med. 368, 777 (2013).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneurol2014253_CR105","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1046\/j.1351-5101.2003.00701.x","volume":"10","author":"P McCrone","year":"2003","unstructured":"McCrone, P. et al. Cost-utility analysis of intravenous immunoglobulin and prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy. Eur. J. Neurol. 10, 687\u2013694 (2003).","journal-title":"Eur. J. Neurol."},{"key":"BFnrneurol2014253_CR106","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1002\/(SICI)1097-4598(199709)20:9<1102::AID-MUS2>3.0.CO;2-C","volume":"20","author":"BM Koffman","year":"1997","unstructured":"Koffman, B. M. & Dalakas, M. C. Effect of high-dose intravenous immunoglobulin on serum chemistry, hematology, and lymphocyte subpopulations: assessments based on controlled treatment trials in patients with neurological diseases. Muscle Nerve 20, 1102\u20131107 (1997).","journal-title":"Muscle Nerve"},{"key":"BFnrneurol2014253_CR107","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1111\/ene.12513","volume":"21","author":"LH Markvardsen","year":"2014","unstructured":"Markvardsen, L. H. et al. Subcutaneous immunoglobulin preserves muscle strength in chronic inflammatory demyelinating polyneuropathy. Eur. J. Neurol. 21, 1465\u20131470 (2014).","journal-title":"Eur. J. Neurol."}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrneurol.2014.253.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneurol.2014.253","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneurol.2014.253.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T12:04:22Z","timestamp":1690805062000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrneurol.2014.253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,6]]},"references-count":107,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["BFnrneurol2014253"],"URL":"https:\/\/doi.org\/10.1038\/nrneurol.2014.253","relation":{},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"value":"1759-4758","type":"print"},{"value":"1759-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,6]]},"assertion":[{"value":"6 January 2015","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}